

29 March, 2007

ASKA Pharmaceutical Co., Ltd.

**ASKA Announces to enter Co-Promotion Agreement of Drugs
for Infertility treatment with Serono Japan**

ASKA Pharmaceutical Co., Ltd. (“ASKA” Tokyo, Japan) today announced that ASKA Pharmaceutical Co., Ltd. and Serono Japan (“Serono Japan”, Tokyo, Japan : an affiliate of Merck Serono SA) have entered into an agreement to co-promote ASKA’s products, GONAPURE INJECTION (Purified Human Menopausal Gonadotrophin) and HMG INJECTION TEIZO (Human Menopausal Gonadotrophin) for infertility treatment in Japan.

Under the Agreement, ASKA and Serono Japan commence the co-promotion of GONAPURE INJECTION and HMG INJECTION TEIZO from April 1, 2007.

Both companies have more than 30 years’ history and high expertise in the infertility treatment. Taking advantage of this occasion, ASKA and Serono Japan will further strengthen their corporation in promotion of awareness campaign in obstetrics and gynecology field.

<Reference>

Purified Human Menopausal Gonadotrophin and Human Menopausal Gonadotrophin are hormones responsible for follicular development, and are widely used as useful treatment for infertility. And the indication of both of GONAPURE INJECTION and HMG INJECTION TEIZO are “Induction of ovulation in hypothalamic and pituitary amenorrhea”.